Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
J Anim Sci ; 95(2): 626-635, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28380607

ABSTRACT

The objective of this project was to evaluate the effects of antimicrobials approved for parenteral metaphylactic use in feeder and stocker calves on morbidity and mortality for bovine respiratory disease with the use of a mixed treatment comparison meta-analysis. An initial literature review was conducted in April 2016 through Pubmed, Agricola, and CAB (Commonwealth Agricultural Bureau) for randomized controlled trials for metaphylaxis antimicrobial administered parentally to incoming feedlot or stocker calves within 48 h of arrival. The final list of publications included 29 studies, with a total of 37 trials. There were 8 different metaphylactic antimicrobials. Final event outcomes were categorized into bovine respiratory disease (BRD) morbidity cumulative incidence d 1 to ≤ 60 of the feeding period, BRD morbidity cumulative incidence d 1 to closeout of the feeding period, BRD mortality cumulative incidence d 1 to closeout of the feeding period, and BRD retreatment cumulative incidence morbidity d 1 to closeout of the feeding period. Network meta-analysis combined direct and indirect evidence for all the event outcomes to determine mean odds ratio (OR) with 95% credibility intervals (CrIs) for all metaphylactic antimicrobial comparisons. The "upper tier" treatment arms for morbidity d 1 to ≤ 60 included tulathromycin, gamithromycin, and tilmicosin. For BRD mortality cumulative incidence d 1 to closeout and BRD retreatment morbidity d 1 to closeout, classifying the treatment arms into tiers was not possible due to overlapping 95% CrIs. The results of this project accurately identified differences between metaphylactic antimicrobials, and metaphylactic antimicrobial options appear to offer different outcomes on BRD morbidity and mortality odds in feedlot cattle.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bovine Respiratory Disease Complex/drug therapy , Animals , Bovine Respiratory Disease Complex/epidemiology , Bovine Respiratory Disease Complex/virology , Cattle , Disaccharides/administration & dosage , Heterocyclic Compounds/administration & dosage , Incidence , Macrolides/administration & dosage , Tylosin/administration & dosage , Tylosin/analogs & derivatives
2.
J Vet Pharmacol Ther ; 39(2): 157-66, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26441021

ABSTRACT

The objectives of this study were to determine (i) whether an association exists between individual pharmacokinetic parameters and treatment outcome when feeder cattle were diagnosed with bovine respiratory disease (BRD) and treated with gamithromycin (Zactran(®) ) at the label dose and (ii) whether there was a stronger association between treatment outcome and gamithromycin concentration in plasma or in the pulmonary epithelial lining fluid (PELF) effect compartment. The study design was a prospective, blinded, randomized clinical trial utilizing three groups of 60 (362-592 lb) steers/bulls randomly allocated within origin to sham injection or gamithromycin mass medication. Cattle were evaluated daily for signs of BRD by a veterinarian blinded to treatment. Animals meeting the BRD case definition were enrolled and allocated to a sample collection scheme consisting of samples for bacterial isolation (bronchoalveolar lavage fluid and nasopharyngeal swabs) and gamithromycin concentration determination (PELF and plasma). Gamithromycin susceptibility of M. haemolytica (n = 287) and P. multocida (n = 257) were determined using broth microdilution with frozen panels containing gamithromycin at concentrations from 0.03 to 16 µg/mL. A two-compartment plasma pharmacokinetic model with an additional compartment for gamithromycin in PELF was developed using rich data sets from published and unpublished studies. The sparse data from our study were then fit to this model using nonlinear mixed effects modeling to estimate individual parameter values. The resulting parameter estimates were used to simulate full time-concentration profiles for each animal in this study. These profiles were analyzed using noncompartmental methods so that PK/PD indices (AUC24 /MIC, AUC∞ /MIC, CMAX /MIC) could be calculated for plasma and PELF (also T>MIC) for each individual. The calculated PK/PD indices were indicative that for both M. haemolytica and P. multocida a higher drug exposure in terms of concentration, and duration of exposure relative to the MIC of the target pathogen, was favorable to a successful case outcome. A significant association was found between treatment success and PELF AUC0-24 /MIC for P. multocida. The calves in this study demonstrated an increased clearance and volume of distribution in plasma as compared to the healthy calves in two previously published reports. Ultimately, the findings from this study indicate that higher PK/PD indices were predictive of positive treatment outcomes.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Body Fluids/metabolism , Bovine Respiratory Disease Complex/drug therapy , Epithelium/metabolism , Macrolides/pharmacokinetics , Animals , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/therapeutic use , Area Under Curve , Body Fluids/chemistry , Bovine Respiratory Disease Complex/metabolism , Cattle , Epithelium/chemistry , Lung , Macrolides/metabolism , Macrolides/therapeutic use , Microbial Sensitivity Tests , Models, Biological
3.
Anim Health Res Rev ; 16(2): 125-34, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26373635

ABSTRACT

The objective of this paper was to perform a critical review of the literature as it pertains to the current status of antimicrobial resistance in pathogens associated with bovine respiratory disease (BRD) in beef cattle and to provide a concise yet informative narrative on the most relevant publications available. As such, the scientific literature contained in PubMed, AGRICOLA, and CAB were searched in February of 2014 for articles related to susceptibility testing of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni from cases of BRD. Titles and abstracts were read and 105 articles that were relevant to the subject of BRD antibiotic resistance were attained for further review. After the application of exclusion criterion (publications must have originated from North America, be in English, adhere to standards set forth by the Clinical and Laboratory Standards Institute, and be concerning antimicrobial resistance in BRD in beef cattle), 16 articles remained and are the focus of this publication. Due to the disparate data from the few studies that investigate susceptibility testing of BRD pathogens, a quantitative assessment or meta-analysis was not performed on the studies presented in this review. However, considering diagnostic lab data, there appears to be a clear trend of a decrease in susceptibility of the three major BRD pathogens to the antimicrobials used commonly for treatment and control of BRD. Studies performing sensitivity testing on healthy cattle report much lower resistance, but it remains unclear if this is because of a true lack of resistance mechanisms, or if the isolates do contain quiescent genes for resistance that are only phenotypically expressed following the administration of an antimicrobial for either treatment or control of BRD. Future research to address this question of genotype and phenotypic expression before and after antimicrobial administration will further advance our knowledge in this area.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bovine Respiratory Disease Complex/drug therapy , Drug Resistance, Bacterial , Animals , Bovine Respiratory Disease Complex/microbiology , Cattle , Mannheimia haemolytica/drug effects , North America , Pasteurella multocida/drug effects , Pasteurellaceae/drug effects , Phenotype
4.
J Anim Sci ; 90(5): 1570-82, 2012 May.
Article in English | MEDLINE | ID: mdl-22573840

ABSTRACT

Contemporary animal agriculture is increasingly criticized on ethical grounds. Consequently, current policy and legislative discussions have become highly controversial as decision makers attempt to reconcile concerns about the impacts of animal production on animal welfare, the environment, and on the efficacy of antibiotics required to ensure human health with demands for abundant, affordable, safe food. Clearly, the broad implications for US animal agriculture of what appears to be a burgeoning movement relative to ethical food production must be understood by animal agriculture stakeholders. The potential effects of such developments on animal agricultural practices, corporate marketing strategies, and public perceptions of the ethics of animal production must also be clarified. To that end, it is essential to acknowledge that people's beliefs about which food production practices are appropriate are tied to diverse, latent value systems. Thus, relying solely on scientific information as a means to resolve current debates about animal agriculture is unlikely to be effective. The problem is compounded when scientific information is used inappropriately or strategically to advance a political agenda. Examples of the interface between science and ethics in regards to addressing currently contentious aspects of food animal production (animal welfare, antimicrobial use, and impacts of animal production practices on the environment) are reviewed. The roles of scientists and science in public debates about animal agricultural practices are also examined. It is suggested that scientists have a duty to contribute to the development of sound policy by providing clear and objectively presented information, by clarifying misinterpretations of science, and by recognizing the differences between presenting data vs. promoting their own value judgments in regard to how and which data should be used to establish policy. Finally, the role of the media in shaping public opinions on key issues pertaining to animal agriculture is also discussed.


Subject(s)
Agriculture/ethics , Agriculture/legislation & jurisprudence , Animal Welfare/ethics , Bioethics/trends , Livestock/physiology , Animals , Anti-Bacterial Agents/administration & dosage , Drug Utilization , Policy
5.
J Vet Pharmacol Ther ; 35 Suppl 1: 93-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22413796

ABSTRACT

Currently, the basis for solubility test conditions and the corresponding solubility criteria is derived from the tremendous wealth of information developed to support human pharmaceutical product development and regulation. However, there are several critical differences between the gastrointestinal tract of ruminants and monogastric species that can affect the conditions and criteria to be applied to the classification of drug solubility in cattle. These include the pH of the stomach, the volume of the stomach, the types of oral formulations, and the definition of 'highest dose'. These points are discussed below and alternative perspectives for consideration with regard to possible modification of solubility criteria for ruminants are presented.


Subject(s)
Cattle/physiology , Gastrointestinal Tract/physiology , Veterinary Drugs/chemistry , Veterinary Drugs/pharmacokinetics , Administration, Oral , Animals , Dosage Forms , Humans , Veterinary Drugs/administration & dosage
6.
J Vet Pharmacol Ther ; 35(3): 231-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21696401

ABSTRACT

Management of pain is of paramount importance for a myriad of indications in human and animal health. Unfortunately, the administration of pain therapeutics is often complicated by insufficient control over pharmacokinetic profiles as a result of frequent oral dosing. Attempts to sustain and tightly control the concentration of these drugs in the blood via controlled release injectable formulations have typically resulted in drug 'burst', followed by marginal control over the ensuing pharmacokinetics. Here, precision particle fabrication (PPF) technology was used to produce uniform microspheres encapsulating the nonsteroidal anti-inflammatory drug meloxicam. After subcutaneous injection, plasma concentrations of meloxicam were held constant in canines for more than 2 weeks without initial drug burst. Pharmacokinetic profiles were accurately modeled using equations typically applied to steady-state infusion. PPF microsphere depots of pain therapeutics or other compounds may ultimately improve safety and sustain the efficacy of medications where such controlled uniform exposure would be therapeutically beneficial.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Microspheres , Thiazines/administration & dosage , Thiazoles/administration & dosage , Animals , Anti-Inflammatory Agents, Non-Steroidal/blood , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Dogs , Female , Injections, Subcutaneous , Male , Meloxicam , Thiazines/blood , Thiazines/pharmacokinetics , Thiazoles/blood , Thiazoles/pharmacokinetics
7.
J Vet Pharmacol Ther ; 33(1): 76-83, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20444029

ABSTRACT

Chlortetracycline HCl (CTC) has impacted profitable livestock production since 1945. However, pharmacokinetic parameters for CTC in ruminating cattle are unavailable in peer-reviewed literature. A total of 18 steers were randomized to 4.4, 11, or 22 mg/kg/day p.o. CTC treatment groups (n = 6). Chlortetracycline treatment was offered as one-half of the daily dose b.i.d. (160 total doses/group) for 80 days. Blood samples were collected at selected time points throughout an 83-day study and analyzed with a solid phase extraction technique and novel ultrahigh performance liquid chromatography-mass spectroscopy/mass spectroscopy analytical method. Noncompartmental analysis (NCA) determined individual pharmacokinetic parameters by treatment group with coefficient of variation (CV %) estimates. A one-compartment open model with first order absorption and elimination, where absorption rate constant was equal to elimination rate constant, was fitted using nonlinear mixed effects modeling (NLMEM). NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA. Dose linearity was confirmed by anova of parameters derived from NCA by treatment group. Further studies are necessary for determining absolute bioavailability and pharmacokinetic-pharmacodynamic relationships of CTC in group fed, ruminating cattle.


Subject(s)
Animal Husbandry , Anti-Bacterial Agents/pharmacokinetics , Cattle/blood , Cattle/metabolism , Chlortetracycline/pharmacokinetics , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Area Under Curve , Chlortetracycline/administration & dosage , Chlortetracycline/blood , Dose-Response Relationship, Drug , Half-Life , Male
8.
J Vet Pharmacol Ther ; 33(2): 196-201, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20444045

ABSTRACT

The American Academy of Veterinary Pharmacology and Therapeutics (AAVPT) and the United States Pharmacopeia (USP) co-sponsored a workshop to explore approaches for developing companion animal antimicrobials. This workshop was developed in response to the shortage of antimicrobials labeled for dogs and cats, as there is a shortage of approved antimicrobials for the range of infectious diseases commonly treated in small animal practice. The objective of the workshop was to identify alternative approaches to data development to support new indications consistent with the unmet therapeutic needs of dogs and cats. The indications for currently approved antimicrobials do not reflect the broader range of infectious diseases that are commonly diagnosed and treated by the veterinarian. Therefore, the labels for these approved antimicrobials provide limited information to the veterinarian for appropriate therapeutic decision-making beyond the few indications listed. Industry, veterinary practice, and regulatory challenges to the development of new antimicrobial indications were discussed. The workshop resulted in short- and long-term recommendations. Short-term recommendations focus on the use of additional data considerations for product labeling. Long-term recommendations center on legislative or regulatory legal initiatives. The workshop recommendations will need collaboration from industry, academia, and regulatory authorities and a legal shift in the drug approval and availability processes.


Subject(s)
Anti-Infective Agents/therapeutic use , Cat Diseases/drug therapy , Communicable Diseases/veterinary , Dog Diseases/drug therapy , Veterinary Drugs/therapeutic use , Animals , Animals, Domestic , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/pharmacology , Cats , Communicable Diseases/drug therapy , Dogs , Drug Approval/legislation & jurisprudence , Legislation, Drug , Research Design , United States , Veterinary Drugs/pharmacokinetics , Veterinary Drugs/pharmacology
9.
J Dairy Sci ; 92(8): 3731-43, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19620655

ABSTRACT

This study examined the efficacy of sodium salicylate for providing analgesia in an amphotericin B-induced bovine synovitis-arthritis model using 10 male Holstein calves, 4 to 6 mo old and weighing approximately 250 kg. The study used a repeated measures partial crossover design with 2 phases, consisting of 3 treatment periods within each phase. Calves were blocked by body weight and randomly assigned to the sodium salicylate (50 mg/kg i.v.) or placebo group for phase 1. In period 1, lameness induction was simulated with a needle prick of the coronary band, followed by drug or placebo administration. At predetermined time points, serial blood samples for cortisol and salicylate concentrations, electrodermal activity measurements, heart rates, and pressure mat data were collected. Visual lameness scores were recorded by an observer blinded to treatments. In period 2, lameness was induced with injection of amphotericin B into the distal interphalangeal joint, followed by drug or placebo administration, with sample collection as described previously. In period 3, the drug or placebo was administered to the respective calves with sample collection. After a 10-d washout period, phase 2 was conducted with treatments crossed over between groups. Cortisol and salicylate samples were analyzed by competitive chemiluminescent immunoassay and fluorescence polarization immunoassay, respectively. The pharmacokinetic data were analyzed using compartmental analysis. Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min. The repeated measures data were analyzed based on a univariate split-plot approach with a random effects-mixed model. Differences in stance phase duration and serum cortisol concentration values were seen both between periods and between treatment group x periods; differences in heart rate, contact surface area, and contact pressure values were seen between periods, suggesting that our lameness model was effective. No differences were seen between treatment groups. When analyzed by visual lameness score, differences were seen in heart rate, contact surface area, contact pressure, and cortisol concentrations. Area under the time-effect curves, determined by using the trapezoidal rule, had results similar to the repeated measures data, except for a difference in period for electrodermal activity. This amphotericin B-induced synovitis-arthritis model is a useful tool for studying changes associated with lameness in cattle. Sodium salicylate was not effective in providing analgesia after lameness.


Subject(s)
Amphotericin B , Arthritis/veterinary , Cattle Diseases/drug therapy , Sodium Salicylate/therapeutic use , Synovitis/veterinary , Animals , Arthritis/chemically induced , Arthritis/drug therapy , Cattle , Cattle Diseases/chemically induced , Hydrocortisone/blood , Lameness, Animal/drug therapy , Male , Random Allocation , Salicylates/blood , Sodium Salicylate/pharmacokinetics , Synovitis/chemically induced , Synovitis/drug therapy , Treatment Outcome
10.
J Vet Pharmacol Ther ; 32(2): 124-8, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19290941

ABSTRACT

The objective of this study was to evaluate the plasma pharmacokinetics of ketamine and its active metabolite norketamine administered intravenously at a dose of 0.1 mg/kg together with xylazine (0.05 mg/kg) to control the pain associated with castration in calves. A two-compartment model with an additional metabolite compartment linked to the central compartment was used to simultaneously describe the time-concentration profiles of both ketamine and its major metabolite norketamine. Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min). Previously published data from rats suggest that the metabolite norketamine contributes to the analgesic effect of ketamine, with a potency that is one-third of the parent drug. An understanding of the time-concentration relationships and the disposition of the parent drug and its metabolite is therefore important for a better understanding of the analgesic potential of ketamine in cattle.


Subject(s)
Adrenergic alpha-Agonists/pharmacokinetics , Anesthetics, Dissociative/pharmacokinetics , Cattle/metabolism , Ketamine/analogs & derivatives , Ketamine/pharmacokinetics , Xylazine/pharmacokinetics , Anesthesia, Intravenous/veterinary , Anesthetics, Dissociative/blood , Animals , Cattle/blood , Chromatography, Liquid/veterinary , Drug Combinations , Ketamine/blood , Male , Orchiectomy/veterinary , Pain/drug therapy , Pain/veterinary
11.
J Vet Pharmacol Ther ; 30(5): 417-21, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17803733

ABSTRACT

A cross-over study design was used to determine the pharmacokinetics of ampicillin in swine. Each of eight pigs was subjected to all of the following three treatments: (1) intramuscular (i.m.) injection of 17.6 mg/kg of ampicillin trihydrate; (2) injection of a mean dose of 17.6 mg/kg of ampicillin trihydrate using a needle-free (NF) injection device; and (3) intravenous injection of 17.6 mg/kg of sodium ampicillin administered as a bolus. Ampicillin trihydrate administered by NF injection in this study was not statistically different from i.m. injection as measured by AUC(0-infinity), MRT, MAT, or Cmax. However, the 90% confidence limits about the difference in NF to i.m. mean Cmax and AUC(0-infinity) values, expressed relative to the i.m. treatment mean, exceeded the traditional bioequivalence limits of +/-20%. In part, failure to demonstrate bioequivalence was attributable to small study size and the large within-subject variability associated with this drug. Therefore the power of this study was not sufficient to definitively prove or disprove bioequivalence and additional studies to describe appropriate dosage regimens for ampicillin trihydrate when administered by NF injection to pigs are warranted.


Subject(s)
Ampicillin/pharmacokinetics , Anti-Bacterial Agents/pharmacokinetics , Swine/metabolism , Ampicillin/administration & dosage , Ampicillin/blood , Animals , Animals, Newborn/metabolism , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Area Under Curve , Cross-Over Studies , Injections, Intramuscular/veterinary , Injections, Intravenous/veterinary , Injections, Jet/veterinary , Male
12.
J Vet Pharmacol Ther ; 30(4): 305-13, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17610403

ABSTRACT

Pain associated with castration in cattle is an animal welfare concern in beef production. This study examined the effect of oral aspirin and intravenous (i.v.) sodium salicylate on acute plasma cortisol response following surgical castration. Twenty bulls, randomly assigned to the following groups, (i) uncastrated, untreated controls, (ii) castrated, untreated controls, (iii) 50 mg/kg sodium salicylate i.v. precastration and (iv) 50 mg/kg aspirin (acetylsalicylic acid) per os precastration, were blood sampled at 3, 10, 20, 30, 40, 50 min and 1, 1.5, 2, 4, 6, 8, 10 and 12 h postcastration. Samples were analyzed by competitive chemiluminescent immunoassay and fluorescence polarization immunoassay for cortisol and salicylate, respectively. Data were analyzed using noncompartmental analysis, a simple cosine model, anova and t-tests. Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h. Plasma salicylate concentrations above 25 microg/mL coincided with significant attenuation in peak cortisol concentrations (P = 0.029). Peak salicylate concentrations following oral aspirin administration was <10 microg/mL and failed to attenuate cortisol response. Once salicylate concentrations decreased below 5 microg/mL, cortisol response in the castrated groups was significantly higher than uncastrated controls (P = 0.018). These findings have implications for designing drug regimens to provide analgesia during routine animal husbandry procedures.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cattle/physiology , Hydrocortisone/blood , Orchiectomy/veterinary , Pain, Postoperative/prevention & control , Sodium Salicylate/pharmacology , Administration, Oral , Animals , Animals, Newborn/physiology , Animals, Newborn/surgery , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Area Under Curve , Cattle/metabolism , Cattle/surgery , Injections, Intravenous/veterinary , Male , Pain, Postoperative/blood , Sodium Salicylate/administration & dosage , Sodium Salicylate/blood , Sodium Salicylate/pharmacokinetics , Sodium Salicylate/therapeutic use
13.
J Vet Pharmacol Ther ; 29(3): 173-83, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16669861

ABSTRACT

The tick-borne rickettsia, Anaplasma marginale, causes the economically important cattle disease anaplasmosis. Once infected, cattle remain lifelong carriers. Herein, we used flow cytometry to test the efficacy of three antimicrobials; oxytetracycline, imidocarb and enrofloxacin against Virginia (VGN) or Oklahoma (OK) A. marginale isolates in short-term erythrocyte cultures. Parasite viability was assessed using the vital dye hydroethidine (HE), which is detectable when living organisms convert HE to ethidium bromide. Viability of A. marginale in selected cultures was determined by subinoculation into susceptible calves. Data were analyzed by MANOVA, Tukey-Kramer honest significant difference and Wilcoxon rank sum tests. Receiver operating characteristic (ROC) analysis was used to correlate results with culture infectivity. Enrofloxacin inhibited A. marginale in a dose dependent manner. Surprisingly, higher concentrations of imidocarb were less effective than lower concentrations against A. marginale with significant differences (P < 0.05) observed between the two isolates. Oxytetracycline was the least active drug tested. Cultures infected with the OK isolate exposed to 4.0 microg/mL enrofloxacin and those of the VGN and OK isolates exposed to 1.0 microg/mL imidocarb were sterilized. This is the first in vitro study demonstrating the efficacy of enrofloxacin against A. marginale. Furthermore, these data indicate that flow cytometry is a useful assay for screening antimicrobials against A. marginale.


Subject(s)
Anaplasma marginale/drug effects , Anaplasmosis/drug therapy , Anti-Bacterial Agents/pharmacology , Cattle Diseases/drug therapy , Anaplasma marginale/classification , Anaplasmosis/epidemiology , Anaplasmosis/microbiology , Animals , Anti-Bacterial Agents/administration & dosage , Cattle , Cattle Diseases/epidemiology , Cattle Diseases/microbiology , Cells, Cultured , Enrofloxacin , Erythrocytes/cytology , Erythrocytes/parasitology , Flow Cytometry/veterinary , Fluoroquinolones/administration & dosage , Fluoroquinolones/pharmacology , Imidocarb/administration & dosage , Imidocarb/pharmacology , Microbial Sensitivity Tests , Oklahoma/epidemiology , Oxytetracycline/administration & dosage , Oxytetracycline/pharmacology , Predictive Value of Tests , ROC Curve , Sensitivity and Specificity , Virginia/epidemiology
14.
J Vet Pharmacol Ther ; 26(3): 173-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12755900

ABSTRACT

Pneumonia caused by Pasteurella (Mannheimia) haemolytica was induced in weaned beef heifer calves, approximately 6 months of age. Calves were treated at 20 h after challenge with therapeutic doses of danofloxacin or tilmicosin. Peripheral blood neutrophils were collected at 3, 24 and 48 h after treatment. The ex vivo effects on neutrophil function, neutrophil apoptosis, and hematological parameters were examined, as was the effect on percentage lung consolidation. Neutrophil function assays included random migration under agarose, cytochrome C reduction, iodination, Staphylococcus aureus ingestion, chemotaxis, and antibody-dependent and antibody-independent cell-mediated cytotoxicity. Apoptosis was determined using a cell death detection kit. Killing was performed at 72 h after treatment. Statistical comparisons were made among the three groups of challenged-treated animals: saline, danofloxacin, and tilmicosin. Comparisons were also made between nonchallenged nontreated animals (NCH) and challenged saline-treated animals. There were no significant differences for any of the neutrophil function assays or neutrophil apoptosis among the challenged-treated groups. This suggests that danofloxacin and tilmicosin have no clinically significant effects on neutrophil function or apoptosis. There were also no significant differences in percentage lung consolidation among the challenged-treated groups. Significant differences were found between the NCH calves and the challenged saline-treated calves in several neutrophil assays, which were attributed to effects of P. haemolytica infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Fluoroquinolones , Macrolides , Mannheimia haemolytica/drug effects , Neutrophils/drug effects , Pasteurellosis, Pneumonic/drug therapy , Tylosin/analogs & derivatives , Tylosin/pharmacology , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Cattle , Injections, Subcutaneous/veterinary , Lung/drug effects , Lung/microbiology , Lung/pathology , Mannheimia haemolytica/pathogenicity , Microbial Sensitivity Tests , Neutrophils/microbiology , Pasteurellosis, Pneumonic/pathology , Phagocytosis/drug effects , Tylosin/administration & dosage , Tylosin/therapeutic use
15.
J Dairy Sci ; 86(3): 792-8, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12703615

ABSTRACT

The effect of intravenous administration of the steroidal drug isoflupredone acetate on lactating dairy cows with mastitis induced using gram-negative bacterial endotoxin was investigated. Cows were randomly assigned to one of four treatment groups: untreated controls, isoflupredone acetate only, mastitis only, and mastitis plus isoflupredone acetate. Isoflupredone acetate was given to treated groups at a dose of 20 mg intravenously, once. Mastitic cows receiving treatment were given isoflupredone acetate after the development of clinical signs. When compared with untreated mastitic controls, cows with endotoxin-induced mastitis treated with isoflupredone acetate did not exhibit measurable differences in heart rate, rectal temperature, rumen motility, or changes in mammary gland surface area in the 14 h following the administration of intramammary endotoxin. Healthy cows treated with isoflupredone acetate had a higher heart rate over the 14 h after drug administration than did untreated healthy controls. When compared with untreated mastitic controls, cows treated with isoflupredone acetate did not exhibit statistically significant differences in milk production following endotoxin-induced mastitis.


Subject(s)
Endotoxins , Fluprednisolone/analogs & derivatives , Fluprednisolone/pharmacology , Mastitis, Bovine/drug therapy , Animals , Body Temperature , Cattle , Female , Fluprednisolone/therapeutic use , Heart Rate , Kinetics , Lactation , Mammary Glands, Animal/pathology , Mastitis, Bovine/chemically induced , Mastitis, Bovine/physiopathology , Muscle Contraction , Rumen/physiopathology
16.
Vet Clin North Am Food Anim Pract ; 17(1): 159-73, vii, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11320693

ABSTRACT

This article reviews some of the issues surrounding antimicrobial use in treating diseases that cause lameness in cattle. The discussion includes sections on selection of an antimicrobial, regimen design, and medication of multiple animals. Pathogen susceptibility testing is covered, along with empiric selection of antimicrobials. Other issues covered include regional perfusion and topical application of antimicrobials, antimicrobials in footbaths and in feed, and withdrawal time estimates.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cattle Diseases/drug therapy , Lameness, Animal/drug therapy , Animals , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Cattle , Cattle Diseases/microbiology , Chemotherapy, Cancer, Regional Perfusion , Lameness, Animal/microbiology , Pharmacokinetics
18.
Antimicrob Agents Chemother ; 44(10): 2777-83, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10991860

ABSTRACT

Salmonella spp. are important food-borne pathogens that are demonstrating increasing antimicrobial resistance rates in isolates obtained from food animals and humans. In this study, 10 multidrug-resistant, cephalosporin-resistant Salmonella isolates from bovine, porcine, and human sources from a single geographic region were identified. All isolates demonstrated resistance to cephamycins and extended-spectrum cephalosporins as well as tetracycline, chloramphenicol, streptomycin, and sulfisoxazole. Molecular epidemiological analyses revealed eight distinct chromosomal DNA patterns, suggesting that clonal spread could not entirely explain the distribution of this antimicrobial resistance phenotype. However, all isolates encoded an AmpC-like beta-lactamase, CMY-2. Eight isolates contained a large nonconjugative plasmid that could transform Escherichia coli. Transformants coexpressed cephalosporin, tetracycline, chloramphenicol, streptomycin, and sulfisoxazole resistances. Plasmid DNA revealed highly related restriction fragments though plasmids appeared to have undergone some evolution over time. Multidrug-resistant, cephalosporin-resistant Salmonella spp. present significant therapeutic problems in animal and human health care and raise further questions about the association between antimicrobial resistance, antibiotic use in animals, and transfer of multidrug-resistant Salmonella spp. between animals and man.


Subject(s)
Cephalosporin Resistance , Salmonella Infections, Animal/microbiology , Salmonella Infections/microbiology , Salmonella/drug effects , Salmonella/genetics , beta-Lactamases/biosynthesis , Animals , Animals, Domestic , DNA, Bacterial/analysis , DNA, Bacterial/genetics , Drug Resistance, Multiple , Electrophoresis, Gel, Pulsed-Field , Humans , Isoelectric Focusing , Microbial Sensitivity Tests , Molecular Epidemiology , Plasmids/genetics , Polymorphism, Restriction Fragment Length , Reverse Transcriptase Polymerase Chain Reaction , beta-Lactamases/genetics
19.
Vet Clin North Am Food Anim Pract ; 14(2): 291-313, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9704416

ABSTRACT

This article discusses therapeutic approaches to conditions commonly encountered in feedlots. Challenges discussed include bovine respiratory complex, tracheal edema, atypical interstitial pneumonia, footrot, toe abscesses, mycoplasma arthritis, cardiovascular disease, lactic acidosis, bloat, coccidiosis, central nervous system diseases, abscesses and cellulitis, pregnancy management and abortion, and ocular disease.


Subject(s)
Cattle Diseases/therapy , Gastrointestinal Diseases/veterinary , Musculoskeletal Diseases/veterinary , Respiratory Tract Infections/veterinary , Abortion, Veterinary/therapy , Abscess/therapy , Abscess/veterinary , Animals , Cardiovascular Diseases/therapy , Cardiovascular Diseases/veterinary , Cattle , Cellulitis/therapy , Cellulitis/veterinary , Central Nervous System Diseases/therapy , Central Nervous System Diseases/veterinary , Coccidiosis/therapy , Coccidiosis/veterinary , Edema/therapy , Edema/veterinary , Eye Diseases/therapy , Eye Diseases/veterinary , Female , Gastrointestinal Diseases/therapy , Musculoskeletal Diseases/therapy , Pneumonia, Atypical Interstitial, of Cattle/therapy , Pregnancy , Pregnancy Complications/therapy , Pregnancy Complications/veterinary , Respiratory Tract Infections/therapy , Tracheal Diseases/therapy , Tracheal Diseases/veterinary
20.
Vet Clin North Am Food Anim Pract ; 14(2): 343-65, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9704419

ABSTRACT

As mentioned at the outset, the ultimate test of a product or procedure must be under field conditions and is best obtained from controlled studies of field use. Economic justification for use is based on this information. Each producer places a different value on attributable benefits such as improved health or growth performance. These values also change with fluctuating market values of cattle and feed. This makes determining the cost-benefit ratio of any procedure or product a moving target. Addressing this issue requires the clinically relevant and statistically significant differences that practitioners should be able to generate if they follow the guidelines presented here. There already exists a number of unusable studies. We suggest that those interested in undertaking this challenge be uncompromising in their experimental design. To be reliable, studies must follow the recommendations outlined above. Without sound field trial design and execution which ensures that the information is reliable and statistical significance which ensures that the differences are real, clinical outcomes cannot be extrapolated to economic justification. Any other course leads to making less than optimal recommendations on product use because of a lack of clinically relevant information.


Subject(s)
Animal Husbandry , Cattle Diseases/therapy , Clinical Trials as Topic , Research Design , Animals , Cattle
SELECTION OF CITATIONS
SEARCH DETAIL
...